View stunning SlideShares in full-screen with the new iOS app!Introducing SlideShare for AndroidExplore all your favorite topics in the SlideShare appGet the SlideShare app to Save for Later — even offline
View stunning SlideShares in full-screen with the new Android app!View stunning SlideShares in full-screen with the new iOS app!
In comparison with using chemotherapy alone, adding the inhibitor allowed the use of up to 70 times lower doses of the chemotherapeutic drugs to kill the same amount of cancer cells.
Additionally, while gemcitabine therapy alone was unsuccessful in pancreatic cancer-bearing mice, adding the TAK-1 inhibitor moved it up to a 78% reduction in tumor volume and increased median average survival from 82 days to 122 days.
Since mice are used to evaluate the safety of many things, we will use mice to complete the procedure. A fixed number of mice with pancreatic cancer will be used to test the effects of TAK-1 and the chemotherapeutic drug called oxaliplatin.
Michel Vulfovich; Caio Rocha-Lima., (2008) Novel Advances in Pancreatic Cancer:Dietary Fructose Consumption Among US Children and Adults: Expert Review of Anticancer Therapy. The Medscape Journal of Medicine . Vol 8(6):993-1002.